Our results demonstrate that a DC vaccine in which the antigen presenting attenuator A20 is inhibited, and that targets FAP-positive CAFs and the tumor antigen TRP2 has potent antitumor effects, enables cross-presentation of tumor antigens by intratumoral APCs resulting in the broad-based induction of T cells specific for tumor antigens not included in the vaccine. Here, FAP is linked to neoplasm.